

# BRAIN

A JOURNAL OF NEUROLOGY

Volume 141 Part 5 May 2018

## Editorial

1235 Editorial: D. M. Kullmann

## Scientific Commentaries

- 1236 The snowball effect of RNA binding protein dysfunction in amyotrophic lateral sclerosis. P. Fratta and A. M. Isaacs
- 1239 Functional 'unlocking': bedside detection of covert awareness after severe brain damage. M. Boly and S. Laureys
- 1241 Is longitudinal tau PET ready for use in Alzheimer's disease clinical trials? O. Hansson and E. C. Mormino
- 1244 Disease progression models for dominantly-inherited Alzheimer's disease. D. Li and M. C. Donohue

## Review articles

- 1247 Perturbed autophagy and DNA repair converge to promote neurodegeneration in amyotrophic lateral sclerosis and dementia. C. Walker and S. F. El-Khamisy
- 1263 Neurotransmitter deficits from frontotemporal lobar degeneration. A. G. Murley and J. B. Rowe

## Original Articles

- 1286 Mechanistic basis of an epistatic interaction reducing age at onset in hereditary spastic paraplegia. T. Newton, R. Allison, J. R. Edgar, et al.
- 1300 Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF- $\beta$ -OTX2-SNAIL via PTEN inhibition. V. Ferrucci, P. de Antonellis, F. P. Pennino, et al.
- 1320 TDP-43 regulates the alternative splicing of hnRNP A1 to yield an aggregation-prone variant in amyotrophic lateral sclerosis. J.-E. Deshaies, L. Sikreta, A. J. Moszczyński, et al.

- 1334 T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention. J. van Langelaar, R. M. van der Vuurst de Vries, M. Janssen, et al.
- 1350 Protein instability, haploinsufficiency, and cortical hyper-excitability underlie STXBP1 encephalopathy. J. Kovačević, G. Maroteaux, D. Schut, et al.
- 1375 Disrupted dynamic network reconfiguration of the language system in temporal lobe epilepsy. X. He, D. S. Bassett, G. Chaitanya, et al.
- 1390 KEAPI inhibition is neuroprotective and suppresses the development of epilepsy. T. Shekh-Ahmad, R. Eckel, S. Dayalan Naidu, et al.
- 1404 Characterization of EEG signals revealing covert cognition in the injured brain. W. H. Curley, P. B. Fargacs, H. U. Voss, et al.
- 1422 Artificial limb representation in amputees. F. M. Z. van den Heiligenberg, T. Orlov, S. N. Macdonald, et al.
- 1434 The striatal kinase DCLK3 produces neuroprotection against mutant huntingtin. L. Galvan, L. Francelle, M.-C. Gaillard, et al.
- 1455 Distinct effects of apathy and dopamine on effort-based decision-making in Parkinson's disease. C. Le Heron, O. Plant, S. Manohar, et al.
- 1470 Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease. A. Nakamura, P. Cuesta, A. Fernández, et al.
- 1486 Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. J. P. Chhatwal, A. P. Schultz, K. A. Johnson, et al.
- 1501 Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease. J. Schulz, G. Pagano, J. A. Fernández Bonfante, et al.
- 1517 Longitudinal tau PET in ageing and Alzheimer's disease. C. R. Jack, Jr, H. J. Wiste, C. G. Schwarz, et al.

- 1529 Data-driven models of dominantly-inherited Alzheimer's disease progression. N. P. Oxtoby, A. L. Young, D. M. Cash, et al.
- 1545 A neurocomputational account of reward and novelty processing and effects of psychostimulants in attention deficit hyperactivity disorder. A. Sethi, V. Voon, H. D. Critchley, et al.
- 1558 Altruistic decisions following penetrating traumatic brain injury. J. Moll, R. de Oliveira-Souza, R. Basilio, et al.

## Dorsal column

### Grey Matter

- 1570 How the coming of the NHS changed British neurology. S. Shorvon

## Letters to the Editor

- e36 The recurrent mutation in *TMEM106B* also causes hypomyelinating leukodystrophy in China and is a CpG hotspot. H. Yan, T. Kubisiak, H. Ji, et al.
- e37 Reply: The recurrent mutation in *TMEM106B* also causes hypomyelinating leukodystrophy in China and is a CpG hotspot. C. Simans, D. Dymont, M. S. van der Knaap, et al.
- e38 Towards personalized therapy for multiple sclerosis: limitations of observational data. E. W. Steyerberg and B. Claggett
- e39 Reply: Towards personalized therapy for multiple sclerosis: limitations of observational data. T. Kalincik
- e40 Noisy but not placebo: defining metrics for effects of neurofeedback. M. Witte, S. E. Kober and G. Wood
- e41 Reply: Noisy but not placebo: defining metrics for effects of neurofeedback. M. Schabus
- e42 Corrigenda

